
    
      The investigators are undertaking a single-center, single-arm study of 20 primary ITP adult
      patients from Shandong University Qilu Hospital

      . All the participants are selected to receive bortezomib treatment (given intravenously at a
      dose of 1.3mg/m2 on days 1,4,8,11). Platelet count, bleeding and other symptoms were
      evaluated before and after treatment. Adverse events are also recorded throughout the study.
    
  